NCT06777017 Can Hepatic-splenic Elastography Predict the Risk of Hepatocellular Recurrence After Radiofrequency Ablation?
| NCT ID | NCT06777017 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | HCC - Hepatocellular Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2022-04-22 |
| Primary Completion | 2025-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2022-04-22 with a primary completion date of 2025-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to assess whether there is an association between hepatic and splenic elastography values and the risk of HCC recurrence after treatment with RFA
Eligibility Criteria
Inclusion Criteria: * Clinical-instrumental diagnosis of chronic liver disease. * Indication for treatment of HCC with RFA using the Barcelona Clinic Liver Cancer (BCLC staging system) classification system19; * Performing hepatic or splenic elastography by transient method with Fibroscan® (Echosens, Paris, France) or ARFI method (ACUSON Sequoia Siemens). * Signature of informed consent Exclusion Criteria: * Age \< 18 years; * Diagnosis of hepatocholangiocarcinoma or other hepatic focal lesions other than hepatocellular carcinoma; * Previous history of liver transplantation (OLT) and/or liver resection for HCC in the previous two years; * Liver disease in decompensation (Child-Pugh C) at the time of informed consent or within three months prior to enrollment; * Patients with other severe and advanced diseases that may affect short-term mortality (e.g. further non-remission neoplasms, heart failure \>NYHA III, chronic renal failure in dialysis, pulmonary diseases dependent on home oxygen therapy).
Contact & Investigator
Rocco Maurizio Zagari, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06777017 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HCC - Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06777017 currently recruiting?
Yes, NCT06777017 is actively recruiting participants. Contact the research team at roccomaurizio.zagari@unibo.it for enrollment information.
Where is the NCT06777017 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06777017 clinical trial?
NCT06777017 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Rocco Maurizio Zagari, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.